ClinicalTrials.gg
RecruitingNCT07708961Updated Oct 26, 2026

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

A Phase 2 interventional study of Archive Sample Retrieval and Biospecimen Collection in Glioblastoma, IDH-Wildtype, sponsored by Mayo Clinic. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Planned enrollment
76th of 221
60 · median 41
Started
2026
with 3 others
Phase 2
99 of 232
13 open now
Primary completion
2036-08
later than 34 of 34 live
Registered
231st of 232
by date
Lead sponsor
4 of 232
Mayo Clinic

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 76th largest by planned enrollment of the 221 interventional ones that give a count, is one of 4 that started in 2026, is one of 99 in phase 2, reaches primary completion later than 34 of the 34 other live ones, and was the 231st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This phase II trial compares the effect of adding WSD0922-FU to temozolomide versus temozolomide alone in slowing disease progression in patients with Epidermal Growth Factor Receptor (EGFR)-mutant, IDH-wildtype glioblastoma. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. WSD0922-FU is a targeted treatment which blocks EGFR. It is able to get into the brain and spinal cord and help treat those types of tumors. Adding WSD0922-FU to the usual treatment with temozolomide may be more effective in slowing disease progression, compared to temozolomide alone, in patients with EGFR-mutant, IDH-wildtype glioblastoma.

03

Conditions studied

  • Glioblastoma, IDH-Wildtype

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Histopathologic diagnosis of glioblastoma, IDH-wildtype [as defined by the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors] on primary pathology review

    • NOTE: MGMT promoter methylation status must have been performed
  • Glioblastomas must have a pathogenic EGFR mutation, with or without EGFR amplification, detected by Clinical Laboratory Improvement Act (CLIA)-certified next-generation sequencing

    • EGFR mutation includes both deoxyribonucleic acid (DNA) sequence variants (e.g. point mutations, etc.) and transcript variants (e.g. EGFRvIII, etc.)
    • EXCEPTIONS: Glioblastomas which are EGFR wildtype with amplification are excluded. Glioblastomas which only have EGFR variants of unknown significance (without any pathogenic EGFR mutations) are also excluded
  • Patients must have completed standard radiation (60 Gy in 30 fractions) with concurrent temozolomide (missing no more than 2 weeks of temozolomide), and adequately recovered from treatment related toxicities

    • NOTE: Adjuvant temozolomide must not have been initiated
  • (ECOG) performance status (PS) 0, 1 or 2
  • > 9.0 g/dL (obtained =\< 14 days prior to registration)
  • Leukocytes > 3.0 x 10\^9/L (obtained =\< 14 days prior to registration)
  • (ANC) > 1.5 x 10\^9/L (obtained =\< 14 days prior to registration)
  • count > 100 x 10\^9/L (obtained =\< 14 days prior to registration)
  • Total =\< 1.5 x (ULN) (\< 3 x ULN for patients with Gilbert's disease) (obtained =\< 14 days prior to registration)
  • (ALT) and aspartate transaminase (AST) =\< 3 x ULN (obtained =\< 14 days prior to registration)
  • (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =\< 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (obtained =\< 14 days prior to registration)
  • Calculated >= 45 mL/min using the Cockcroft-Gault formula (obtained =\< 14 days prior to registration)
  • Negative pregnancy test done =\< 7 days prior to registration, for persons of only
  • Provide written
  • Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
  • Must be willing to take light-protective measures during the study and for two weeks after last dose of WSD0922-FU
  • Willingness to provide mandatory tissue specimens for correlative research

Exclusion criteria

Exclusion Criteria:

  • Patients deemed to have progressive disease based on clinical deterioration after chemoradiation or radiographic progression outside of the radiation field

    • EXCEPTION: Patients deemed to have pseudoprogression are eligible; however, this should be controlled on =\< 4 mg of dexamethasone and should not require bevacizumab at study onset
  • Any of the following because this study involves an agent, the genotoxic, mutagenic and teratogenic effects of which on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of (and persons able to father a child) who are unwilling to employ adequate
  • Any of the following prior therapies:

    • Surgery for glioblastoma =\< 3 weeks prior to registration
    • Radiation therapy =\< 2 weeks prior to registration
    • Systemic therapies intended for the management of the glioblastoma, including but not limited to:

      • Targeted therapies
      • EGFR inhibitors
      • Alkylating chemotherapy
      • Adjuvant temozolomide (note that temozolomide administered concurrent with radiation is NOT an exclusion criterion)
      • Immunotherapy
      • Biologics
      • Any other systemic therapies [Food and Drug Administration (FDA) approved, off-label, investigational]
      • Bevacizumab
    • Non-enzyme-inducing anticonvulsants \< 2 weeks prior to registration
    • Strong inducers and strong inhibitors of \< 14 days prior to registration
  • Failure to adequately recover from any adverse events or complications related to any of the following therapies received prior to registration:

    • Craniotomy and resection of tumor
    • Stereotactic of tumor
    • Other major surgical procedure
    • Radiation therapy \< 2 weeks prior to registration
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. Examples include (but are not limited to) nausea and vomiting (if not controlled by supportive therapy), inability to swallow the formulated product, previous significant bowel resection, other chronic gastrointestinal diseases, etc
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Severe skin lesions such as skin/pressure ulcers, chronic leg ulcers or non-healing wounds.
    • Active history of keratitis
    • Symptomatic CNS complications that require urgent neurosurgical or medical (e.g. mannitol) intervention
    • Known intracranial hemorrhage which is unrelated to tumor
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Dyspnea at rest due to complications of advanced or other disease that requires continuous oxygen therapy
    • Or psychiatric illness/social situations that would limit compliance with study requirements
  • patients and patients known to be positive and currently receiving antiretroviral therapy

    • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Other active malignancy within the last 3 years that would interfere with treatment on this protocol

    • EXCEPTIONS: non-melanoma skin cancer, carcinoma in situ of the cervix, patients on hormonal therapy for treated breast or prostate cancer
  • History of myocardial infarction =\< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A (temozolomide, WSD0922-FU)

    Patients receive temozolomide PO QD on days 1-5 of cycles 1-6 and WSD0922-FU PO BID on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease recurrence while on therapy and are planning to undergo tumor resection or stereotactic biopsy prior to starting alternative treatment continue receiving WSD0922-FU PO BID on days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle until the time of surgery. Patients also undergo ECHO and MRI throughout the trial and undergo chest x-ray and collection of tissue samples on study. Patients may undergo optional collection of blood and/or cerebrospinal fluid (CSF) samples throughout the trial.

    Procedure: Archive Sample Retrieval · Procedure: Biospecimen Collection · Procedure: Chest Radiography · Procedure: Echocardiography Test · Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU · Procedure: Magnetic Resonance Imaging · Drug: Temozolomide

  • Active comparator
    Arm B (temozolomide)

    Patients receive temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience disease recurrence while on therapy and are planning to undergo tumor resection or stereotactic biopsy prior to starting alternative treatment may initiate WSD0922-FU PO BID on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days until the time of surgery. Patients also undergo ECHO and MRI throughout the trial and undergo chest x-ray and collection of tissue samples on study. Patients may undergo optional collection of blood and/or CSF samples throughout the trial.

    Procedure: Archive Sample Retrieval · Procedure: Biospecimen Collection · Procedure: Chest Radiography · Procedure: Echocardiography Test · Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU · Procedure: Magnetic Resonance Imaging · Drug: Temozolomide

Interventions

  • ProcedureArchive Sample Retrieval

    Archived tumor specimens will be retrieved if available from original surgery for glioblastoma.

  • ProcedureBiospecimen Collection

    Undergo collection of blood, cerebrospinal fluid (CSF), and/or tumor tissue samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureChest Radiography

    Undergo chest x-ray

    Also known as: Chest X-ray

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • DrugEGFR/EGFRvIII Inhibitor WSD0922-FU

    Drug page: EGFR/EGFRvIII Inhibitor WSD0922-FUStudies of EGFR/EGFRvIII Inhibitor WSD0922-FUEGFR/EGFRvIII Inhibitor WSD0922-FU pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU, EGFR Mutant Inhibitor WSD0922-FU, WSD 0922-FU, WSD-0922-FU, WSD0922-FU

  • ProcedureMagnetic Resonance Imaging

    Undergo brain MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given PO

    Also known as: CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Defined as the time from randomization to the time of documented disease progression or death. PFS will be evaluated for each arm, where patients will be evaluated based on the treatment arm to which they were randomized and will include only those who are eligible and have received any protocol therapy to be considered evaluable. PFS distributions will be graphically and quantitatively compared using Kaplan-Meier methods. These methods will be used to estimate the median PFS as well as 1-year estimates for PFS by treatment arm along with corresponding 95% confidence intervals. Cox proportional hazards models will also be used to assess influential factors on PFS both in the univariate and the multivariable settings.

    Time frame: Up to 5 years

Secondary outcomes

  1. Incidence of adverse events (safety and tolerability)

    Safety and tolerability will be evaluated by treatment regimen. Adverse events (AEs) will be summarized per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 , and where toxicities will be defined as adverse events that are deemed to be at least possibly treatment-related (i.e., attribution of "possibly", "probably", or "definite"). The maximum grade for each type of treatment-related AE will be recorded for each patient, and the frequency of each will be summarized by treatment arm. Frequency tables and graphical evaluations of AEs and treatment-related AEs will be summarized and evaluated to assess if there are any patterns or differences in the rates or types of AEs.

    Time frame: Up to 30 days after last dose

  2. Overall survival

    Defined as the time from randomization to the time of death. Kaplan Meier methods will be used to estimate key aspects of the overall survival distributions for each of the treatment arms, and log rank tests will be used to compare these distributions between arms. If patients randomized to the control arm choose to receive WSD0922-FU upon documented recurrence/progressive disease, then will also utilize more complex approaches to evaluate overall survival that accommodates different time periods of receiving treatment.

    Time frame: Up to 5 years

  3. Overall response rate (ORR)

    The objective response classifications and best responses observed for patients will be summarized by treatment arm. These will be classified based on review as the proportion of patients who achieve any response to treatment (ORR, including minor, partial, or complete response) as well as those who achieve a partial or complete response to therapy divided by the total number of patients randomized and treated on that arm. Assuming that the number of patients who respond to therapy on each arm is binomially distributed, will estimate these proportions along with corresponding 95% confidence intervals.

    Time frame: Up to 5 years

07

Study locations

3 of 3 sites recruiting
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
    Recruiting
    • Cancer Center Clinical Trials · Contact507-293-6386
    • Shannon P Fortin Ensign, MD, PhD · Principal investigator
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224-9980, United States
    Recruiting
    • Cancer Center Clinical Trials · Contact507-293-6386
    • Wendy J. Sherman, MD · Principal investigator
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Cancer Center Clinical Trials · Contact507-293-6386
    • Sani H. Kizilbash, MD, MPH · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2036, 120 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 120 months is above that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Aug 31, 2036
CompletionEst.
Aug 31, 2036
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 15, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Mayo Clinic in Arizona · Scottsdale, United Statesno status→Recruiting
  • Mayo Clinic in Florida · Jacksonville, United Statesno status→Recruiting
  • Mayo Clinic in Rochester · Rochester, United Statesno status→Recruiting
across 2 updates, Oct 15, 2026 – Oct 26, 2026
Contact
Study contact now listed: added m•••@mayo.edu · •••0015; added •••6386. See the current contact
Oct 15, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Mayo Clinic in Arizona · Scottsdale, United StatesContact added •••6386Contact added (no phone or email listed)
  • Mayo Clinic in Rochester · Rochester, United StatesContact added •••6386Contact added (no phone or email listed)
  • Mayo Clinic in Florida · Jacksonville, United StatesContact added •••6386Contact added (no phone or email listed)
across 2 updates, Oct 15, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Mayo Clinic in Florida is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic in Florida · Jacksonville, United StatesContact added •••6386Contact added (no phone or email listed)
  2. Oct 15, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    3 sites changed recruiting status (2 now recruiting, 1 now suspended)
    Show 3 sites
    • Mayo Clinic in Arizona · Scottsdale, United Statesno status→Recruiting
    • Mayo Clinic in Florida · Jacksonville, United Statesno status→Suspended
    • Mayo Clinic in Rochester · Rochester, United Statesno status→Recruiting
    Contact Study contact now listed: added m•••@mayo.edu · •••0015; added •••6386. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Mayo Clinic in Arizona · Scottsdale, United StatesContact added •••6386Contact added (no phone or email listed)
    • Mayo Clinic in Rochester · Rochester, United StatesContact added •••6386Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07708961
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Aug 28, 2026
Primary completion
Aug 31, 2036 (estimated)
Completion
Aug 31, 2036 (estimated)
Last update
Oct 26, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Cancer Center Clinical Trials
Contact
507-293-6386
Sani H. Kizilbash, MD, MPH
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: EGFR/EGFRvIII Inhibitor WSD0922-FU · Temozolomide

Start the discussion